NCT03208257Unknown2 期
Esmolol to Control Adrenergic Storm in Septic Shock- ROLL-IN 2
Samuel Brown1 个研究点 分布在 1 个国家目标入组 10 人开始时间: 2017年8月7日最近更新:
适应症
干预措施
相关药物
试验速览
- 阶段
- 2 期
- 发起方
- 入组人数
- 10
- 试验地点
- 1
- 主要终点
- Organ-failure-free days
研究概览
简要总结
Septic shock is a common syndrome caused by the body's response to an infection. Septic shock is responsible for 10% of all ICU admissions and 30% of ICU deaths. Use of "beta blocker" medications may improve outcomes after septic shock. This pilot study evaluates protocols to infuse the beta blocker esmolol in patients with septic shock.
详细描述
This is a prospective, single arm, feasibility study of esmolol infusion in septic shock. The objective is to evaluate the feasibility, adequacy, and efficiency of study protocols for a subsequent ECASSS study. This study (ECASSS-R2) extends observations made in an initial pilot, ECASSS-R.
研究设计
- 研究类型
- Interventional
- 分配方式
- Na
- 干预模型
- Single Group
- 主要目的
- Treatment
- 盲法
- None
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Age ≥ 18 years
- •Within 72 hours of admission to the ICU and septic shock (sepsis present at time of admission)
- •a. Septic shock defined by SEPSIS-3 consensus criteria as i. Suspected or documented infection ii. Sequential Organ Failure Assessment (SOFA) score increased by at least 2 points over baseline iii. Lactate > 2mmol/L iv. Receiving vasopressors to treat hypotension after at least 20 ml/kg intravenous crystalloid volume expansion
- •Receiving vasopressors through a central venous catheter for more than 60 minutes.
- •Arterial catheter in place or expected to be placed imminently.
- •Heart rate > 90/min while receiving vasopressors for more than 60 minutes.
- •Adequately volume expanded, as manifest by any of the following, performed as part of routine clinical care (i.e., no study procedures will be performed before signed consent). If none of these measures are clinically available, the clinical attending must confirm that volume expansion is adequate. (After enrollment, a final safety check will confirm the adequacy of volume expansion.)
- •Central venous pressure (CVP) > 15 mm Hg.
- •Negative Passive-Leg Raise (PLR) maneuver (<10% increase in cardiac output after PLR).
- •No cardiac output response (<10% increase) after rapid infusion (<5 min) of 250 ml of IV crystalloid (i.e., a graded volume expansion challenge [GVEC]).
- •Inferior vena cava (IVC) plethora
- •For patients who happen to be breathing passively (i.e., paralyzed or deeply sedated) on a positive pressure mechanical ventilator delivering at least 8 ml/kg tidal volumes and in normal sinus rhythm, stroke volume variability <13% (such patients are acknowledged to be uncommon; the protocol does not recommend or require the induction of passive breathing).
排除标准
- •Lack of informed consent.
- •Currently receiving ExtraCorporeal Membrane Oxygenation (ECMO).
- •Known pregnancy or nursing.
- •Patient is a prisoner.
- •Patient on hospice (or equivalent comfort care approach) at or before the time of enrollment.
- •Known or current atrial fibrillation.
- •Previously enrolled in the trial.
- •Known allergy to esmolol or vehicle (see Appendix 2 for BREVIBLOC vehicle ingredients).
- •Receipt of nodal blocking agents (see Appendix 3 for list of such agents) within three half lives
- •Hemoglobin < 7 gm/dl.
- •Cardiac arrest within 24 hours.
- •Pulmonary hypertension (moderate or severe), from documented history of prior right heart catheterization or current evidence on transthoracic echocardiogram (TTE) of any of the following
- •Mean Pulmonary Arterial Pressure (mPAP) ≥ 35mmHg (millimeters of mercury)
- •Systolic Pulmonary Arterial Pressure (SPAP) ≥ 60mmHg (millimeters of mercury)
- •Cardiovascular collapse, as manifested by inability to achieve a mean arterial pressure (MAP) of 65 mmHg with vasopressor therapy.
- •Cardiogenic shock, as defined by any of the following
- •Cardiac index ≤ 2.3 L/min/m2
- •Ejection fraction ≤ 30%
- •ScvO2 ≤ 60%
- •Current infusion of any dose of dobutamine, milrinone, or dopamine (if dopamine is being used for clinically diagnosed bradycardia or cardiogenic shock)
- •Current infusion of epinephrine for clinically diagnosed cardiogenic shock
- •Significant atrioventricular dysfunction
- •Sick sinus syndrome
- •PR interval > 200 msec
- •Current evidence or prior history of Grade 2 or Grade 3 heart block
- •Pacemaker or plans to place a pacemaker
- •Pheochromocytoma or status asthmaticus
- •Receiving clonidine, guanfacine, or moxonidine
- •Worse than moderate aortic stenosis
- •Known aortic stenosis, with any of (1) mean gradient ≥ 40 mmHg OR (2) maximum gradient ≥ 60mmHg OR (3) aortic valve area ≤ 1.0cm2 OR (4) aortic valve area index ≤ 0.85cm2/m2 body surface area.
- •Worse than mild mitral stenosis
- •Known mitral stenosis, with any of (1) valve area ≤ 1.5 cm2 OR mean gradient ≥ 5 mmHg.
研究组 & 干预措施
Esmolol
Experimental
Intravenous esmolol will be administered as a continuous infusion according to protocol to control tachycardia with maximal infusion rates in the range of 10-40 mcg/kg/min.
干预措施: Esmolol (Drug)
结局指标
主要结局
Organ-failure-free days
时间窗: 28 days
次要结局
- ICU-free days(28 days)
- All-cause hospital mortality(During hospitalization)
- Peak serum high-sensitivity troponin(24 hours)
- All-cause 28-day and 90-day mortality(28 days and 90 days)
- Left ventricular (LV) longitudinal strain(24 hours)
研究者
Samuel Brown
Associate Professor, Pulmonary and Critical Care Medicine
Intermountain Health Care, Inc.
研究点 (1)
Loading locations...
相似试验
已完成
2 期
Esmolol Infusion for Patients With Septic Shock and Persistent TachycardiaSeptic ShockNCT02841241Intermountain Health Care, Inc.7
进行中（未招募）
不适用
Esmolol to treat tachicardia in septic shock - Esmolol in septic shockMedDRA version: 9.1Level: LLTClassification code 10043071septic shockEUCTR2010-023495-11-ITAZIENDA UNIVERSITARIA POLICLINICO UMBERTO I DI ROMA
Unknown
2 期
Esmolol Effects on Heart and Inflammation in Septic ShockSeptic ShockNCT02068287Central Hospital, Nancy, France25
Unknown
不适用
The Effect of Esmolol on Patients With SepsisSepsisNCT04537767Shanghai Zhongshan Hospital120
终止
2 期
Esmolol to Treat the Hemodynamic Effects of Septic ShockTachycardiaSeptic ShockHypotensionNCT02369900Beth Israel Deaconess Medical Center40